Home Archive
Archive
2025 Volume 46 Issue 11  Published: 2025-11-10
    Topic
  • Hongling MA , Guleng Siri
    doi: 10.13683/j.wph.2025.11.001

    Adverse drug reactions (ADR) is a significant global public health concern, with notably increasing incidence rates and economic costs in China. Traditional ADR surveillance relying on spontaneous reporting systems suffers from delays and data incompleteness. The advancement of artificial intelligence (AI) technologies offers innovative solutions for ADR monitoring, enhancing efficiency and accuracy. This article reviewed the core technologies and current application status of AI, focusing on elucidating implementation scenarios and challenges in ADR early warning systems, aiming to provide references for AI-assisted ADR management strategies.

  • Topic
  • Zhuguang ZHANG , Hongxu LYU , Yaxuan HE , Zhijia HUANG , Guleng Siri , Xiaoxia WANG
    doi: 10.13683/j.wph.2025.11.002

    Sepsis associated-acute lung injury (SA-ALI), as a serious clinical condition, seriously threatens patients'lives and health, and its high morbidity and mortality rate pose a great challenge to medical work. Currently, early diagnosis of SA-ALI is difficult, and it is hard to accurately grasp the progression of the disease, and the treatment plan lacks personalization, leading to poor prognosis of patients. In recent years, artificial intelligence technology has brought hope for the diagnosis and treatment of SA-ALI. This article reviewed the early diagnosis, targeted treatment and prognosis management of SA-ALI by artificial intelligence, providing a multidimensional solution for SA-ALI and promoting the innovation of clinical diagnosis and treatment towards precision.

  • Article
  • Yanman GAO , Jiajia SUN , Hongye CAO , Jun ZHANG
    doi: 10.13683/j.wph.2025.11.003
    Objective

    To explore the mechanism of Chaiyin Yajia formula on subacute thyroiditis (SAT) by inhibiting NOD-like receptor family protein (NLRP)3 inflammasome.

    Methods

    Thirty SAT patients (STA group) admitted to the hospital from June to December, 2024 and 30 healthy subjects (healthy control group) matched during the same period were selected. Peripheral venous blood was collected from all subjects. The contents of interleukin (IL)-6, IL-1β and tumor necrosis factor (TNF)-α, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), NLRP3 inflammasome, caspase-1 and apoptosis-associated speck-like protein containing a CARD (ASC) were determined by enzyme linked immunosorbent assay (ELISA).Human thyroid normal cells Nthy-ori 3-1 were treated with 25 ng/mL TNF-α to construct the thyroid cell inflammation model, and they were divided into the TNF-α group and the TNF-α+Yajia formula group (TNF-α treatment followed by intervention with 90 μg/mL Chaiyin Yajia formula solution). At the same time, blank control groups were set up (without any processing). The expression levels of apoptosis-related proteins (caspase-3 and caspase-9) and NLRP3, caspase-1, and ASC proteins were detected by western blotting. The apoptosis rate of cells was detected by flow cytometry.

    Results

    Compared with the healthy control group, the levels of IL-6, IL-1β, TNF-α, ESR, CRP and the contents of NLRP3, caspase-1 and ASC, of patients in the SAT group were significantly increased (P<0.05). Compared with the control group, the levels of IL-6, IL-1β and TNF-α in the cells of the TNF-α group, the protein expressions of caspase-3 and caspase-9, the apoptosis rate, and the protein expression levels of NLRP3, caspase-1 and ASC were all significantly increased (P<0.05). Compared with the TNF-α group, the levels of IL-6, IL-1β, and TNF-α, the protein expressions of caspase-3 and caspase-9, the apoptosis rate, and the protein expression levels of NLRP3, caspase-1, and ASC in the TNF-α+Yajia formula group were significantly decreased (P<0.05).

    Conclusion

    Chaiyin Yajia formula can reduce cellular inflammatory responses, suppress cell apoptosis, and alleviate thyroid cell damage by inhibiting the activation of NLRP3 inflammasome, which is of great significance for SAT treatment. Inhibiting the activation of NLRP3 inflammasome may become a new therapeutic strategy for SAT.

  • Article
  • Jianhui WU , Linna JIA , Lihua SHEN
    doi: 10.13683/j.wph.2025.11.004
    Objective

    To explore the clinical efficacy of traditional Chinese medicine acupoint application combined with bionic physical electrical stimulation in the treatment of postpartum rectus abdominis diastasis (RAD).

    Methods

    A total of 300 women with RAD in our hospital from December 2020 to October 2024 were selected as research objects and randomly divided into control group, bionic physical electrical stimulation treatment group (electrical stimulation group)and traditional Chinese medicine acupoint application combined with electrical stimulation treatment group (combined treatment group), with 100 cases in each group. The patients were treated with expectant therapy, bionic physical electrical stimulation, and Chinese medicine acupoint application combined with electrical stimulation, once every other day, 5 times as a course, with an interval of 20 days, and a total of 2 courses. The total effective rate of RAD, the improvement of, low back pain, and adverse reactions before and after treatment were compared among the three groups.

    Results

    Compared with the control group, the total effective rate of RAD in both the electrical stimulation group and the combined treatment group were increased, and the combined treatment group was superior to the electrical stimulation group, with statistically significant differences (P<0.001). After two courses of treatment, there was no statistically significant difference in the improvement of low back pain among the three groups (P>0.05). During the treatment process, no adverse reactions such as local pain, numbness or infection occurred in any of the three groups.

    Conclusion

    Traditional Chinese medicine acupoint application combined with bionic physical electrical stimulation is safe and effective in the treatment of RAD.

  • Article
  • Lijun ZHAO , Rong XU , Li LI , Chang LIU
    doi: 10.13683/j.wph.2025.11.005
    Objective

    To explore the efficacy of ivabradine in patients with acute myocardial infarction (AMI)complicated with heart failure (HF) and its influence on cardiac function and inflammatory factors.

    Methods

    A total of 240 patients with AMI combined with HF who were admitted to our hospital from January 2022 to January 2024 were selected and randomly divided into the observation group and the control group, with 120 cases in each group. The control group was given conventional treatment, while the observation group was treated with ivabradine tablets in addition. Both groups were treated continuously for 10 weeks. The clinical efficacy, left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), mean pulmonary artery pressure (MPAP), central venous pressure (CVP), pulmonary vascular resistance (PVR), soluble suppression of tumorigenicity 2 protein (sST2), troponin (cTn)Ⅰ, N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor (TNF)-α, interleukin (IL)-6 and adverse reactions were compared between the two groups.

    Results

    After treatment, the total effective rate of the observation group was 90.00%, significantly higher than 78.33% of the control group (P<0.05). The LVEF of the observation group was higher than that of the control group, while LVEDD and LVESD were lower than those of the control group. The differences were all statistically significant (P<0.05). The MPAP, CVP and PVR in the observation group were all lower than those in the control group, and the differences were statistically significant (P<0.05). The levels of serum sST2, cTnⅠ and NT-proBNP in the observation group were all lower than those in the control group, and the differences were statistically significant (P<0.05). The levels of serum hs-CRP, TNF-α and IL-6 in the observation group were all lower than those in the control group, and the differences were statistically significant (P<0.05). There was no statistically significant difference in the comparison of adverse reactions between the two groups (P>0.05).

    Conclusion

    Ivabradine is helpful to improve the therapeutic effect of AMI combined with HF, and has good safety. It is worthy of clinical promotion.

  • Article
  • Jianing WANG , Wenmei ZHANG , Chun YANG , Xiaowen LI , Xinlei GUO , Li ZUO
    doi: 10.13683/j.wph.2025.11.006
    Objective

    To evaluate the clinical efficacy of recombinant human erythropoietin-Fc (rhEPO-Fc) at different doses and frequencies in Chinese patients with renal anemia receiving maintenance hemodialysis (MHD).

    Methods

    A total of 180 patients with RA receiving MHD from 41 research centers across the country from February 2018 to May 2019 were included. Patients were randomly assigned to the rhEPO-Fc 18 μg/kg per week group, rhEPO-Fc 24 μg/kg per week group, and rhEPO-Fc every 2 weeks 24 μg/kg group by block randomization, with 60 cases in each group. All patients were treated with rhEPO-Fc for 12 weeks, during which the dosage was adjusted according to hemoglobin (Hb).The outcome measures included the Hb level, reticulocyte count and number of dose adjustments.

    Results

    After treatment, the proportions of patients whose Hb increased by at least 10 g/L or reaching 110 g/L in the three groups were 73.60%, 77.60% and 52.20% respectively. The reticulocyte counts in the three groups increased by (19.63±32.51)×109/L, (18.16±26.24)×109/L and (40.38±27.91)×109/L respectively, compared with before treatment. The proportions of patients who underwent dose adjustment due to decreased Hb levels in the three groups were 73.33%, 56.67% and 63.33%, and 51.67%, 61.67% and 18.33% in patients who underwent dose adjustment due to increased Hb levels.

    Conclusion

    Administration of rhEPO-Fc once every 1 or 2 weeks can effectively improve the anemia status of MHD patients, and 18 μg/kg per week can be used as the recommended dose for subsequent larger-scale clinical studies.

  • Article
  • Xiaowen CAO , Peng WANG , Shuo FENG , Zhongju XU , Lu YE , Jiwei FENG
    doi: 10.13683/j.wph.2025.11.007
    Objective

    To observe the clinical effect of tonifying kidney and reducing turbidity decoction combined with external application of kidney failure umbilical therapy decoction in the treatment of chronic renal failure (CRF).

    Methods

    A total of 70 patients with CRF diagnosed in Shanghai Gongli Hospital of Pudong New Area from March 2023 to December 2024 were selected and randomly divided into a treatment group and a control group, with 35 cases in each group. The control group was given basic Western medical treatment, while the treatment group was treated with oral administration of traditional Chinese medicine combined with umbilical therapy, both groups were treated for 8 weeks.The total effective rate, serum creatinine (Scr), estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN), serum uricacid (SUA), interleukin (IL)-6 and hypersensitive C-reactive protein (hs-CRP) were compared between the two groups.

    Results

    The total effective rate of the treatment group was better than that of the control group (91.43% vs.71.43%, P<0.05). After treatment, the levels of Scr and SUA in the treatment group were lower than those in the control group (P<0.05), and the level of eGFR was higher than that in the control group (P<0.05). There was no significant change in BUN between the two groups (P>0.05). The levels of IL-6 and hs-CRP in both groups were decreased compared with before (P<0.05), and the level of IL-6 in the treatment group was lower than that in the control group (P<0.05). There was no significant difference in the reduction amplitude of hs-CRP levels between the two groups (P>0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).During the treatment period, no serious adverse events or deterioration of the condition occurred in either group of patients, such as doubling of serum creatinine levels, entering dialysis status, or hospitalization due to heart failure.

    Conclusion

    The internal and external treatment method of Tonifying Kidney and Reducing Turbidity has a better effect in delaying the deterioration of renal function in CRF with deficiency of both spleen and kidney, and has good safety. Its mechanism of action may be related to the inhibition of inflammatory factors.

  • Article
  • Ran MA , Hongxia XIE , Qiang HE , Yuxin MA
    doi: 10.13683/j.wph.2025.11.008
    Objective

    To explore the cosmetic effects of modified Mahuang Lianqiao Chixiaodou decoction on patients with chronic facial urticaria, and to seek a good solution to promote patient recovery.

    Methods

    A total of 122 patients with chronic facial urticaria admitted to the Dermatology Department of our hospital from June 2022 to January 2024 were randomly assigned into groups using 1∶1 block randomization. The Western medicine group (n=61) was treated with ebastin tablets, and the combined traditional Chinese medicine group (n=61) was treated with modified Mahuang Lianqiao Chixiaodou decoction on the basis of the Western medicine group. The therapeutic effects, adverse reactions, cosmetic effects, interleukin (IL)-17 and IL-23 levels before and after treatment, as well as urticaria activity score (UAS), dermatology life quality index (DLQI) score, and the disease recurrence rate 6 months after treatment were observed of the two groups.

    Results

    The total effective rate of the combined traditional Chinese medicine group was higher than that of the Western medicine group (P<0.05). The adverse reaction rates of the both groups were both lower, and the difference was not statistically significant (P>0.05). The cosmetic effect of the combined traditional Chinese medicine group was better than that of the Western medicine group (P<0.05). The disease recurrence rate of patients in the combined traditional Chinese medicine group was lower than that of the Western medicine group after 6 months of treatment (P<0.05). The levels of IL-17 and IL-23, as well as the UAS and DLQI scores, decreased in both groups of patients after treatment, and the combined traditional Chinese medicine group were lower than those in the Western medicine group (P 0.05).

    Conclusion

    The modified Mahuang Lianqiao Chixiaodou decoction has a good therapeutic effects on the treatment of chronic urticaria on the face. It can also enhance the patients’ cosmetic effect, improve their symptoms and quality of life, reduce the recurrence rate of the disease, and offers good safety.

  • Article
  • Zhaoyang LI , Quanjian WEI , Hailong LIU
    doi: 10.13683/j.wph.2025.11.009
    Objective

    To explore the therapeutic effect of iguratimod combined with Tripterygium wilfordii multiglucoside tablets in the treatment of rheumatoid arthritis (RA) and its influence on knee joint function.

    Methods

    A total of 130 RA patients admitted to Linquan County People's Hospital from January 2022 to December 2024 were selectively included in the study and randomly divided into the observation group and the control group, with 65 cases in each group. The control group was treated with iguratimod, while the observation group was treated with iguratimod combined with Tripterygium wilfordii multiglucoside tablets. The clinical efficacy, C reactive protein (CRP), and anticyclic citrullinated peptide antibody (ACPA), knee joint function score, effusion depth, synovial thickness and the occurrence of adverse reactions of the two groups were compared.

    Results

    After treatment, the total effective rate of the observation group was higher than that of the control group (89.23% vs. 73.85%, P<0.05). The levels of serum CRP and ACPA in both groups were lower than those before treatment (P<0.05), and those in the observation group were lower than those in the control group (P<0.05). The hospital for special surgery scores of both groups were lower than those before treatment (P<0.05), and the scores of the observation group were lower than those of the control group (P<0.05). The Lysholm scores of both groups were increased compared with those before treatment (P<0.05), and the scores of the observation group were higher than those of the control group (P<0.05). The depth of effusion and the thickness of synovial membrane in both groups were lower than those before treatment (P<0.05), and the decrease in the observation group was greater (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, but the difference was not statistically significant (12.31% vs. 9.23%, P>0.05).

    Conclusion

    RA patients can benefit significantly from the treatment of iguratimod combined with Tripterygium wilfordii multiglucoside tablets. Among them, Tripterygium wilfordii multiglucoside tablets, as an adjuvant therapy, can effectively reduce CRP levels, inhibit ACPA activity, and improve knee joint function, without increasing the risk of adverse reactions, and has good safety.

  • Article
  • Xuebao TENG , Zhenxi WANG , Xin ZHANG
    doi: 10.13683/j.wph.2025.11.010
    Objective

    To explore the influencing factors of recurrence in children with cough variant asthma (CVA)one year after discontinuation of inhaled glucocorticoid treatment.

    Methods

    A retrospective analysis was conducted on the clinical data of 165 children with CVA who discontinued inhaled glucocorticoid therapy for one year from January 2022 to January 2024 in our hospital. Univariate analysis was used, and variables with P<0.05 were included in multivariate logistic regression analysis to investigate the influencing factors of recurrence in children with CVA one year after discontinuation of inhaled glucocorticoid treatment.

    Results

    There were statistically significant differences (P<0.05) in family awareness of CVA prevention and control, frequency of respiratory infections during follow-up, history of rhinitis, season of discontinuation, forced expiratory volume in 1 second/forced vital capacity ratio at discontinuation, fractional exhaled nitric oxide (FeNO), and 25-hydroxyvitamin D[25 (OH)D] levels between the two groups. Multivariate logistic regression analysis showed that family awareness of CVA prevention and control, frequency of respiratory infections during follow-up, season of discontinuation, FeNO levels at discontinuation, and 25 (OH)D levels were the independent influencing factors for CVA recurrence one year after discontinuation of inhaled glucocorticoid therapy (P<0.05).

    Conclusion

    The low awareness of CVA prevention and control among family members, the high frequency of respiratory tract infections during the follow-up period, the drug withdrawal season in winter and spring, the high FeNO level at the time of drug withdrawal, and the low 25 (OH)D level are all risk factors for recurrence of CVA patients one year after drug withdrawal after receiving inhaled glucocorticoid treatment.

  • Article
  • Weihua PENG , Xiaoke SHANG , Changdong ZHANG , Shu'na XIAO
    doi: 10.13683/j.wph.2025.11.011
    Objective

    To explore the efficacy and mechanism of sodium-glucose cotransporter (SGLT)-2 inhibitor dapagliflozin in the treatment of patients with heart failure with preserved ejection fraction (HFpEF).

    Methods

    HFpEF patients admitted to Fugou Huimin Hospital of Traditional Chinese Medicine from January 2023 to December 2024 were selected as the subjects and divided into the observation group and the control group, with 50 cases in each group.The control group was treated with conventional therapy, while the observation group was treated with dapagliflozin in combination. The changes of echocardiographic indicators, inflammatory factors, cardiac function indicators and myocardial fibrosis indicators in the two groups were compared, and the incidences of adverse reactions and major cardiovascular event (MACE) were also compared.

    Results

    After treatment, the left ventricular end-diastolic diameter, left ventricular end-systolic diameter, peak velocity of early mitral valve blood flow/peak velocity of early mitral valve annulus in the observation group were all lower than those in the control group, and the left ventricular ejection fraction was higher, with significant differences (P<0.05). The levels of high-sensitivity C-reactive protein, interleukin-6, N-terminal pro-brain natriuretic peptide, creatine kinase, creatine kinase isoenzyme, α -hydroxybutyrate dehydrogenase, soluble growth-stimulating expression gene 2 protein, connective tissue growth factor, and matrix metalloproteinase-9 in the observation group were all lower than those in the control group, and the differences were all significant (P<0.05).After a 3-month follow-up, the incidence of MACE in the observation group was lower than that in the control group (P<0.05).

    Conclusion

    Dapagliflozin has a significant short-term therapeutic effect on patients with HFpEF, which can reduce the inflammatory response of the body, improve cardiac function and myocardial fibrosis, and lower the incidence of short-term MACE. Moreover, it has good safety.

  • Article
  • Xin ZHAO , Susu LI , Zengqing MA , Lianping WU , Guoping SUN
    doi: 10.13683/j.wph.2025.11.012
    Objective

    To investigate and analyze the adverse event (AE) signals associated with trastuzumab deruxtecan, and provide scientific basic for clinical use and regulatory decision-making.

    Methods

    AE reports related to trastuzumab deruxtecan from its market launch to Nov 24, 2024, were retrieved from the WHO-VigiAccess and FAERS databases. Disproportionality analysis methods, including reporting odds ratio, proportional reporting ratio, and Bayesian confidence propagation neural network, were used for signal detection.

    Results

    A total of 12 545 reports from WHO-VigiAccess and 5 924 reports from the FAERS database related to trastuzumab deruxtecan were included. A total of 243 significant AE signals were identified, involving 20 system organ classification, with a focus on general disorders and administration site reactions, gastrointestinal disorders, respiratory, thoracic and mediastinal disorders, and blood and lymphatic system disorders. Additionally, 114 new potential risk signals were detected (accounting for 46.91%), including weight gain, ascites, pleural effusion, sepsis, pulmonary embolism, and PJP.

    Conclusion

    Continuous monitoring of drug safety is essential during trastuzumab deruxtecan therapy to maximize therapeutic outcomes and minimize risks.

  • Review
  • Xinyue CHEN , Yanzhe WANG
    doi: 10.13683/j.wph.2025.11.013

    Transfer RNA-derived small RNA (tsRNA) is a tRNA fragment produced by cutting precursors or mature tRNA through endonucleases. It has functions such as regulating gene expression, epigenetics and immune responses. It has been confirmed to play a role in multiple system diseases and their tumors, and is closely related to kidney diseases.This paper reviewed the generation and classification of tsRNA, its biological functions, and its role in kidney diseases, and elaborated on the significance of tsRNA as an early diagnostic marker and therapeutic target for kidney diseases, aiming to provide a reference for clinical practice.

  • Review
  • Yanyan ZENG , Siqian PENG , Yan ZHENG , Qihang YU , Na NI , Junlong Wang
    doi: 10.13683/j.wph.2025.11.014

    In 2022, the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association jointly released a clinical practice guideline that introduced the term progressive pulmonary fibrosis (PPF) to collectively refer to the progressive fibrotic phenotypes of interstitial lung diseases other than idiopathic pulmonary fibrosis (IPF). These diseases may exhibit clinical course characteristics and core mechanisms of fibrosis similar to those of IPF, even after standardized treatment. Currently, the two anti-fibrotic drugs nintedanib and pirfenidone approved by the U.S. Food and Drug Administration, can only slow the decline in lung function in patients with IPF, but cannot reverse fibrosis. Due to the significant heterogeneity of PPF patient population and complex enrollment criteria, clinical trials targeting PPF often terminate due to recruitment challenges. Consequently, current drug development strategies primarily select IPF as the initial indication and then gradually expand to other fibrotic lung diseases after confirming effectiveness. In the research and development pipeline, most candidate drugs remain in the early stages of clinical development, with only a few advancing to phase Ⅱ/Ⅲ clinical studies and simultaneously exploring the PPF indication. Notably, in 2024, the world's first anti-fibrotic drug designed entirely using artificial intelligence (AI), INS018-055, successfully progressed to Phase Ⅱ clinical trials, marking a significant breakthrough application of AI technology in drug development. This article systematically dissected the conceptual framework of PPF, covering its definition, disease spectrum, epidemiological characteristics, and molecular mechanisms, while reviewed the latest clinical research advancements from the perspective of anti-fibrotic treatment, aiming to provide a theoretical foundation for the discovery of new targets and translational research.

  • Review
  • Jiajie XIE , Danfei LOU
    doi: 10.13683/j.wph.2025.11.015

    Mild cognitive impairment 、 (MCI) is a common neurodegenerative disease that is characterized by memory impairment or progressive decline in other cognitive domains. The incidence of MCI among people aged 65 and above is 7.7% to 28.3%, and 10% to 15% of these patients will progress to dementia. Early intervention for MCI can alleviate the impact of cognitive dysfunction on quality of life as well as reduce the prevalence of dementia in patients.Currently, the treatment methods for MCI in western medicine are limited and poor effective. In recent years, the safety and efficacy of using traditional Chinese medicine (TCM) to treat MCI under the guidance of TCM theories have been effectively verified in clinical practice. Meanwhile, modern science and technology have also revealed the possible mechanism of TCM prevention and treatment of MCI from the aspects of inhibiting β-amyloid deposition, Tau protein hyperphosphorylation, inflammatory response, oxidative stress and regulating cholinergic system. This article reviewed the clinical application and mechanism research progress of TCM in treating MCI.

  • Pharmacy administration
  • Xutao WANG , Miao WANG , Hong SU
    doi: 10.13683/j.wph.2025.11.016
News